- Home
- AOMR vs CLLS Comparison
AOMR vs CLLS Comparison
Compare AOMR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- CLLS
- Stock Information
- Founded
- AOMR 2018
- CLLS 1999
- Country
- AOMR United States
- CLLS France
- Employees
- AOMR N/A
- CLLS N/A
- Industry
- AOMR Real Estate Investment Trusts
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- AOMR Real Estate
- CLLS Health Care
- Exchange
- AOMR Nasdaq
- CLLS Nasdaq
- Market Cap
- AOMR 240.9M
- CLLS 240.2M
- IPO Year
- AOMR 2021
- CLLS 2007
- Fundamental
- Price
- AOMR $10.24
- CLLS $1.89
- Analyst Decision
- AOMR Buy
- CLLS Buy
- Analyst Count
- AOMR 5
- CLLS 2
- Target Price
- AOMR $11.50
- CLLS $8.00
- AVG Volume (30 Days)
- AOMR 162.1K
- CLLS 22.5K
- Earning Date
- AOMR 11-05-2024
- CLLS 11-04-2024
- Dividend Yield
- AOMR 12.48%
- CLLS N/A
- EPS Growth
- AOMR N/A
- CLLS N/A
- EPS
- AOMR 1.97
- CLLS N/A
- Revenue
- AOMR $69,248,000.00
- CLLS $19,635,000.00
- Revenue This Year
- AOMR N/A
- CLLS $271.02
- Revenue Next Year
- AOMR $30.57
- CLLS $33.48
- P/E Ratio
- AOMR $5.21
- CLLS N/A
- Revenue Growth
- AOMR N/A
- CLLS N/A
- 52 Week Low
- AOMR $7.60
- CLLS $0.96
- 52 Week High
- AOMR $13.32
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- AOMR 36.01
- CLLS 30.12
- Support Level
- AOMR $10.12
- CLLS $1.95
- Resistance Level
- AOMR $10.47
- CLLS $2.08
- Average True Range (ATR)
- AOMR 0.25
- CLLS 0.11
- MACD
- AOMR 0.03
- CLLS -0.04
- Stochastic Oscillator
- AOMR 30.69
- CLLS 0.00
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rates and credit cycles.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.